Merck & Co., Inc. (MRK) Tops Q4 EPS by 2c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Leerink Swann Downgrades Merck (MRK) to Market Perform
February 4, 2013 7:20 AM ESTLeerink Swann downgraded Merck (NYSE: MRK) from Outperform to Market Perform.
The firm cited: "(1) reduced prospects with the delay/uncertainty around odanacatib, (2) increasing 2013+ competition vs. Januvia & Isentress as well as the outcome of Germany's (G-BA/AMNOG) planned assessment of DPP-IV inhibitors, (3) ongoing investor... More
